- Home
- GNRC vs ITCI Comparison
GNRC vs ITCI Comparison
Compare GNRC & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNRC
- ITCI
- Stock Information
- Founded
- GNRC 1959
- ITCI 2002
- Country
- GNRC United States
- ITCI United States
- Employees
- GNRC N/A
- ITCI N/A
- Industry
- GNRC Metal Fabrications
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- GNRC Consumer Discretionary
- ITCI Health Care
- Exchange
- GNRC Nasdaq
- ITCI Nasdaq
- Market Cap
- GNRC 9.7B
- ITCI 8.0B
- IPO Year
- GNRC 2010
- ITCI N/A
- Fundamental
- Price
- GNRC $143.88
- ITCI $76.33
- Analyst Decision
- GNRC Buy
- ITCI Strong Buy
- Analyst Count
- GNRC 20
- ITCI 11
- Target Price
- GNRC $156.94
- ITCI $97.00
- AVG Volume (30 Days)
- GNRC 582.5K
- ITCI 454.4K
- Earning Date
- GNRC 07-31-2024
- ITCI 10-31-2024
- Dividend Yield
- GNRC N/A
- ITCI N/A
- EPS Growth
- GNRC 62.49
- ITCI N/A
- EPS
- GNRC 3.90
- ITCI N/A
- Revenue
- GNRC $4,021,807,000.00
- ITCI $564,526,000.00
- Revenue This Year
- GNRC $7.94
- ITCI $46.60
- Revenue Next Year
- GNRC $8.91
- ITCI $37.06
- P/E Ratio
- GNRC $36.31
- ITCI N/A
- Revenue Growth
- GNRC N/A
- ITCI 54.31
- 52 Week Low
- GNRC $79.86
- ITCI $45.50
- 52 Week High
- GNRC $169.57
- ITCI $84.89
- Technical
- Relative Strength Index (RSI)
- GNRC 43.32
- ITCI 56.57
- Support Level
- GNRC $139.66
- ITCI $73.05
- Resistance Level
- GNRC $143.61
- ITCI $76.98
- Average True Range (ATR)
- GNRC 4.19
- ITCI 1.74
- MACD
- GNRC -0.89
- ITCI 0.32
- Stochastic Oscillator
- GNRC 20.52
- ITCI 77.92
About GNRC Generac Holdlings Inc.
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.